Celltrion Signs Contract for Pharmaceutical Contract Development and Manufacturing Worth 111.2 Billion KRW

[Asia Economy Reporter Kwon Jaehee] Celltrion announced on the 19th that it has signed a contract with TEVA Pharmaceuticals International GmbH for the contract development and manufacturing of the active pharmaceutical ingredient of the migraine treatment Ajovy® worth 111.2 billion KRW. This amount corresponds to 5.8% of the sales revenue in 2021.

The contract period is from August 19, 2022, to March 31, 2024.